Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011
Cash flows from operating activities:
Net income	$ 1,360,040		$ 823,855
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	178,162		106,380
Earnings of equity method investments, net of distributions	169		198
Gain on sale of marketable equity securities	(326)		0
Deferred income taxes	22,728		4,520
Equity based compensation expense	25,399		15,535
Change in fair value - derivative instruments	(10,977)		(5,920)
(Increase) decrease in current assets:
Accounts receivable	(29,474)		495,971
Inventories	(370,831)		(195,575)
Income taxes receivable	53,465		51,034
Prepayments and other	16,690		7,778
Increase (decrease) in current liabilities:
Accounts payable	(96,263)		(403,762)
Income taxes payable	110,533		182,468
Accrued liabilities	(6,166)		28,999
Turnaround expenditures	(74,612)		(27,985)
Other, net	(6,749)		5,707
Net cash provided by operating activities	1,171,788		1,089,203
Cash flows from investing activities:
Additions to properties, plants and equipment	(178,235)		(98,428)
Increase in cash due to merger with Frontier	0		872,158
Investment in Sabine Biofuels	(2,000)		(9,125)
Purchases of marketable securities	(236,315)		(370,042)
Sales and maturities of marketable securities	(212,216)		(194,386)
Net cash provided by (used for) investing activities	(233,636)		413,154
Cash flows from financing activities:
Principal tender on senior notes	(205,000)		(15)
Purchase of treasury stock	(190,307)		(38,955)
Structured stock repurchase arrangement	8,620		0
Contribution from joint venture partner	6,000		27,500
Dividends	(382,610)		(129,377)
Excess tax benefit from equity based compensation	16,021		1,399
Deferred financing costs	(3,289)		(11,724)
Other	(1,165)		(857)
Net cash used for financing activities	(459,648)		(148,599)
Cash and cash equivalents:
Increase for the period	478,504		1,353,758
Beginning of period	1,578,904		229,101
End of period	2,057,408		1,582,859
Cash paid during the period for:
Interest	77,184		50,570
Income taxes	622,314		225,499
HEP [Member]
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	38,683	[1]	22,407	[1]
Cash flows from investing activities:
Additions to properties, plants and equipment	(29,302)		(175,795)
Cash flows from financing activities:
Borrowings under credit agreement - HEP	523,000		93,000
Repayments under credit agreement - HEP	(292,000)		(50,000)
Net proceeds from issuance of senior notes - HEP	294,750		0
Principal tender on senior notes	(185,000)		0
Distributions to noncontrolling interest	(43,749)		(37,929)
Purchase of units for incentive grants - HEP	(4,919)		(1,641)
Cash and cash equivalents:
Beginning of period	6,369
End of period	$ 1,993

[1] HEP acquired our 75% interest in UNEV in July 2012. As a result, we have recast our HEP segment information to include the UNEV Pipeline operations as a consolidated subsidiary of HEP for all periods presented. For the three and nine months ended September 30, 2012, UNEV Pipeline revenues were $3.0 million and $10.8 million, respectively. The UNEV Pipeline was previously presented under Corporate and Other.